With a $35 million Series B financing in hand, BiPar Sciences Inc. expects to generate Phase II data with lead product candidate BSI-201, advance a second compound into the clinic and get a third product through IND filing. (BioWorld Today)

In a merger valued at $670 million, Seattle-based biotech Ikaria Inc. is joining forces with Clinton, N.J.-based INO Therapeutics Inc., the specialty pharmaceutical division of The Linde Group. The new company, Ikaria Holdings, will focus on gas-based critical care therapeutics. (BioWorld Today)

In a merger valued at $670 million, Seattle-based biotech Ikaria Inc. is joining forces with Clinton, N.J.-based INO Therapeutics Inc., the specialty pharmaceutical division of The Linde Group. The new company, Ikaria Holdings, will focus on gas-based critical care therapeutics. (BioWorld Today)